Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Stader, F.; Decosterd, L.; Stoeckle, M.; Cavassini, M.; Battegay, M.; Saldanha, S.A.; Marzolini, C.; Courlet, P.

doi:10.1097/QAD.0000000000002489

Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Details

Request a copy

Serval ID

serval:BIB_6666EE49EABD

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Aging does not impact drug--drug interaction magnitudes with antiretrovirals.

Journal

AIDS

Author(s)

Stader F., Decosterd L., Stoeckle M., Cavassini M., Battegay M., Saldanha S.A., Marzolini C., Courlet P.

Working group(s)

and the Swiss HIV Cohort Study

ISSN

1473-5571 (Electronic)

ISSN-L

0269-9370

Publication state

Published

Issued date

01/05/2020

Peer-reviewed

Oui

Volume

Number

Pages

949-952

Language

english

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

: The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH aged at least 55 years. DDI magnitudes were comparable with those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar.

Keywords

Aged, Aged, 80 and over, Aging, Amlodipine/adverse effects, Amlodipine/therapeutic use, Anti-Retroviral Agents/therapeutic use, Antiretroviral Therapy, Highly Active, Atorvastatin/adverse effects, Atorvastatin/therapeutic use, Cardiovascular Agents/adverse effects, Cardiovascular Agents/therapeutic use, Cardiovascular Diseases/drug therapy, Cardiovascular Diseases/epidemiology, Darunavir/adverse effects, Darunavir/therapeutic use, Drug Interactions, Female, HIV Infections/drug therapy, HIV Infections/epidemiology, Heterocyclic Compounds, 3-Ring/adverse effects, Heterocyclic Compounds, 3-Ring/therapeutic use, Humans, Male, Middle Aged, Oxazines/adverse effects, Oxazines/therapeutic use, Piperazines/adverse effects, Piperazines/therapeutic use, Pyridones/adverse effects, Pyridones/therapeutic use, Rosuvastatin Calcium/adverse effects, Rosuvastatin Calcium/therapeutic use, Treatment Outcome

OAI-PMH

oai:serval.unil.ch:BIB_6666EE49EABD

DOI

10.1097/QAD.0000000000002489

Pubmed

32028327

Web of science

000562484200019

Open Access

Yes

Create date

17/02/2020 15:57